Baidu
map

福建省将17种抗癌药纳入医保报销目录

2018-10-27 吴振东 新华网

近日,福建省医疗保障管理委员会(以下简称“福建省医保办”)发布消息,将最新被纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的17种国家谈判药品纳入福建省医保药品目录乙类范围,按国家规定的限定支付范围执行,自10月25日起执行,九个地市同步执行,第一天已有肺癌患者成功得到药物报销,享受到国家医保谈判福利。福建省是率先落地本轮国家谈判抗癌药品的省份之一。

近日,福建省医疗保障管理委员会(以下简称“福建省医保办”)发布消息,将最新被纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的17种国家谈判药品纳入福建省医保药品目录乙类范围,按国家规定的限定支付范围执行,自10月25日起执行,九个地市同步执行,第一天已有肺癌患者成功得到药物报销,享受到国家医保谈判福利。福建省是率先落地本轮国家谈判抗癌药品的省份之一。

今年6月,国家医疗保障局开启了新一轮的抗癌药医保准入专项谈判工作。历时三个月的谈判,最终有17个药品获得谈判成功。10月10日,国家医疗保障局印发通知,将17种药品纳入《国家基本医疗保险、工伤保险和生育保险药品目录(2017年版)》乙类范围,同时要求各省(区、市)药品集中采购机构要在2018年10月底前将谈判药品按支付标准在省级药品集中采购平台上公开挂网。医保经办部门要及时更新信息系统,确保11月底前开始执行。福建省比国家医保局规定时间提前了1个多月。

福建省医保办发文之后,全省各地市即刻开展落地工作,确定17种通过国家谈判的抗癌药纳入各地市医保支付范围,确定医保支付标准,调整医保支付比例为70%左右。同时落实招标平台公开挂网、医疗机构采购、临床医生使用和医保报销落地等各方统筹协调,切实降低患者的用药负担。截至目前,全省已有5家医院可以成功处方医保报销的三代肺癌靶向药,其中包括:福建省肿瘤医院、福建省立医院、厦门弘爱医院、厦门大学附属第一医院、福建省南平市人民医院。

10月12日,泉州市在全省率先出台将2018年17种国家谈判的抗癌药纳入医保支付范围、确定医保支付标准,同时还调整了2017年部分国家谈判抗癌药品医保支付比例,降低患者用药负担。泉州市医保局相关负责人表示,这次国家通过谈判大幅度降低抗癌药品价格,对群众来说就是一项实实在在的惠民好政策,要第一时间让群众得到实惠,尽早享受到改革成果红利。

据悉,本次纳入国家和福建省医保目录的17个抗癌药品中包括12个实体肿瘤药和5个血液肿瘤药,均为临床必需、疗效确切的肿瘤治疗药品,涉及非小细胞肺癌、肾癌、直肠癌、黑色素瘤、淋巴瘤等多个癌种。谈判药品价格降幅也非常给力,大部分进口药品谈判后的支付标准低于周边国家或地区市场价格,平均低36%。同时与市场平均零售价相比,17个谈判药品的平均降幅达56.7%。

尤其是在非小细胞肺癌治疗领域,有5个产品入选,成为入选产品最多的治疗领域,其中三代肺癌靶向药物奥希替尼降价超过了70%。依此推算,肺癌患者使用奥希替尼治疗肺癌的花费也将由谈判前的51000元/月,降至15300元/月,同时受惠于省级医保政策,还可实现70%左右的报销,肺癌患者的经济负担将大大减轻。

福建省立医院胸外科主任潘小杰教授指出:“我国大多数肺癌患者在接受一代、二代EGFR-TKI药物治疗一年左右的时间,便会产生耐药,有三分之二的患者出现了T790M突变。奥希替尼是第三代肺癌口服靶向药,可以解决由于T790M突变而引起的耐药问题。此次奥希替尼等纳入我省医保支付范围,医保患者自付的年度治疗费用仅为降价前年治疗费用的1/4,大大降低了患者的个人负担。”

福建省肿瘤医院放疗科主任李建成教授表示:“医保目录的实施将帮助更多患者选择正规渠道的药物,接受规范化的治疗,不再因为价格原因而选择非正规途径获取药物而延误病情,错过最佳治疗时机。我们希望未来能有更多省份落实相关政策,进一步提升正规渠道的肺癌靶向治疗药物的可及性,肿瘤患者因此也可以获得更为规范的治疗,从而延长生命、提高生活质量。”


福建省肿瘤医院放疗科主任李建成教授

谈及此次国家医保抗癌药专项谈判,已经成功拿到医保报销药物的福建肺癌患者王女士道出了大多数肺癌患者的心声,她说:“得知这次国家医保谈判的结果,我感到既高兴又忐忑,因为不知道报销比例是多少、什么时候能享受医保价格、后续申请流程是否复杂、医院里是否有药等。以前靶向药物价格昂贵,往往会给普通家庭带来沉重负担。之前每个月几万元的药费,现在医保报销后个人每个月只要支付四千多元,就可以用上之前负担不起、疗效好的进口抗癌药。希望其他患者也能和我一样幸运,可以尽快享受到医保福利。此次医保降价能够帮助大家以合理的价格获得正规渠道的药物。感谢国家和政府对我们肿瘤患者生存现状和经济负担的关注和重视,希望未来能有更多的创新抗癌药能更快进入医保,帮助更多肿瘤患者减负。”

据悉,截至目前已有浙江、四川、湖南、内蒙古、宁夏等地政府已正式发文,宣布11月将正式执行国家医保谈判结果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2019-05-23 ewsr9
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-29 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-28 天地飞扬

    了解一下,谢谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1655071, encodeId=40f416550e13e, content=<a href='/topic/show?id=49d8e4680a4' target=_blank style='color:#2F92EE;'>#福建省#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74680, encryptionId=49d8e4680a4, topicName=福建省)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5b1b24623883, createdName=ewsr9, createdTime=Thu May 23 03:29:00 CST 2019, time=2019-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061057, encodeId=ca13206105e87, content=<a href='/topic/show?id=a933560e126' target=_blank style='color:#2F92EE;'>#报销目录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56071, encryptionId=a933560e126, topicName=报销目录)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Tue Jul 23 14:29:00 CST 2019, time=2019-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647524, encodeId=3e04164e52434, content=<a href='/topic/show?id=38043385561' target=_blank style='color:#2F92EE;'>#医保报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33855, encryptionId=38043385561, topicName=医保报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a3823444828, createdName=guguangxiang, createdTime=Mon Nov 19 23:29:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314814, encodeId=1b1d1314814d0, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545741, encodeId=205a1545e411d, content=<a href='/topic/show?id=8df5560640e' target=_blank style='color:#2F92EE;'>#报销#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56064, encryptionId=8df5560640e, topicName=报销)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=718013815880, createdName=ms705947299214030, createdTime=Mon Oct 29 14:29:00 CST 2018, time=2018-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350770, encodeId=648b350e70db, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Oct 28 14:00:19 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350732, encodeId=0742350e32d1, content=感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eb131638261, createdName=lietome24, createdTime=Sun Oct 28 09:04:33 CST 2018, time=2018-10-28, status=1, ipAttribution=)]
    2018-10-28 lietome24

    感谢小编为我们准备了如此丰盛的精神大餐,同时也向作者致谢!认真学习了,点赞!

    0

相关资讯

福建组建省卫生健康委员会

近日,福建省委办公厅、省政府办公厅印发《福建省省级机构改革实施方案》,明确组建福建省卫生健康委员会,要求今年11月中旬前挂牌,年底前完成“三定”工作。

福建仿制药企享税收优惠

福建省政府办公厅近日出台《关于改革完善仿制药供应保障及使用政策的实施意见》规定,仿制药企业经认定为高新技术企业的可享受税收优惠政策。

孙春兰在福建调研时强调扎实推进医改政策落地见效

中共中央政治局委员、国务院副总理孙春兰15日至17日在福建调研时强调,要深入学习贯彻习近平总书记关于卫生与健康工作的重要论述,聚焦突出问题,深化改革攻坚,推动党中央、国务院关于全面深化医改的决策部署落地见效,不断增进人民群众的健康福祉。

福建鼓励名老中医在农村社区办诊所

近日,福建省人民政府办公厅印发《关于支持社会力量提供多层次多样化医疗服务的实施意见》,提出多项支持举措,发展多样化中医药服务。

福建明确差异化医院投入政策

福建省政府办公厅近日出台《关于建立现代医院管理制度的实施意见》,明确各地要落实政府保障责任,根据经济发展和财政增速状况,执行不同等级、不同类别医院差别化常态化的投入政策。

福建省降低社会办医门槛 鼓励发展全科医疗服务

日前,福建省出台支持社会力量提供多层次多样化医疗服务的实施意见,进一步激发社会办医积极性。意见提出,到2020年,福建省将打造一批有较强服务竞争力的社会办医疗机构,形成若干具有影响力的特色健康服务产业集聚区,服务供给基本满足省内需求,逐步形成多层次多样化医疗服务新格局。为此,福建省将鼓励发展全科医疗服务。支持社会力量举办高水平全科诊所,建立包括全科医生、护士以及诊所管理人员在内的专业协作团队,为

Baidu
map
Baidu
map
Baidu
map